Articles related to GLYCEMIC CONTROL

In a study including 73 meta-analyses and 8,601 unique articles, sugar consumption was associated with 18 endocrine/metabolic outcomes, 10 cardiovascular outcomes, seven cancer outcomes, and 10 other outcomes. Endocrine/metabolic outcomes included weight gain, ectopic fat accumulation, obesity, and cardiovascular disease, which were largely attributed to excessive consumption of fructose containing sugars.

In a study of patients with DM2, 75 years old and over, continuous glucose monitoring revealed that 65% had glucose level two times below range (<54 mg/dL during ≥15 consecutive minutes) between midnight and 6 a.m. Fewer than half of the patients detected the hypoglycemic episode via self-monitoring. Because hypoglycemia episodes are associated with long-term complications, continuous glucose monitoring (CGM) could be used to improve care in these patients.

Getting a handle on the biochemical processes that govern how food is broken down and used within the body can be a daunting task for many, and even for those who understand it, monitoring with technology isn’t always possible. This is where Levels come into play. An instant metabolic analysis just a few hours after eating is only the beginning of the Levels experience; the app focuses on four major blood glucose levers in a gamified experience: diet, exercise, stress, and sleep. Dr. Lauren Kelley-Chew, Levels’ Head of Clinical Product, discusses all of this and more.

The study was conducted while GLP-1 RAs and SGLT-2 inhibitors were still considered second-line therapies; however, in a 2022 Consensus Report, the American Diabetes Association and the European Association for the Study of Diabetes recommended these medications as first-line therapy for people with type 2 diabetes who have or are at high risk of certain complications such as heart failure, CKD, and atherosclerotic cardiovascular disease (ASCVD). Are the medications’ price tag keeping people away?

Whether prescribing them for diabetes or weight loss, what factors should you consider when choosing among the seven approved GLP-1 agonist formulations? This concise review highlights the variables.

The results of these trials show that vitamin D reduced the risk of diabetes progression by 3% to 18% after three years, with serum 25-hydroxy D levels of at least 125 nmol/L showing the greatest benefit. Vitamin D was also associated with a 30% increase in the likelihood of returning to normal glucose regulation.